Can You Take Wegovy to Lose 10 Pounds? What Clinical Evidence Actually Shows

What STEP 1 tells us about 10-pound losses, and why target size is the wrong frame

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight plus a weight-related condition. Over 68 weeks, those on semaglutide 2.4mg lost around 15% of their body weight on average, against roughly 2.4% on placebo. For a person starting at 90 kg, that is 13.5 kg, or close to 30 pounds. For someone at 75 kg, 15% is about 11 kg, roughly 24 pounds.

A 10-pound loss sits comfortably inside that range for most eligible participants. But here is the thing: Wegovy was not designed around a specific pound target. It was designed to produce meaningful, sustained weight reduction in people whose BMI places them in the overweight-with-comorbidity or obese category. The question a prescriber asks is not "do you want to lose 10 pounds?", it is "does your health profile meet the licensed criteria, and would you benefit clinically?"

If your answer to that second question is yes, a 10-pound loss is almost certainly within reach. If your BMI is already close to the lower licensed threshold, a prescriber may still approve treatment, but the conversation will focus on your overall health, not the number.

The BMI eligibility line, and why 10 pounds alone does not cross it

UK licensing for Wegovy sets clear starting points: a BMI of 30 or above, or a BMI between 27 and 29.9 if you have at least one weight-related condition such as raised blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. The NICE recommendation for semaglutide (TA875) goes further, restricting NHS access to specialist weight management services for people with higher BMIs and comorbidities, but private prescribing follows the licensed criteria rather than the NICE commissioning route.

What this means in practice: if you want to lose 10 pounds and your BMI is 31, you may well be eligible. If your BMI is 24 and you are simply aiming for a lighter version of yourself for a wedding or a holiday, you would not meet the licensed threshold, and a responsible prescriber would not approve treatment. Wegovy is not a cosmetic medicine; the MHRA has been explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss.

Lower BMI thresholds (2.5 kg/m² lower) apply for some ethnic backgrounds under UK guidance, your prescriber accounts for this during assessment. The BMI thresholds that apply to Wegovy in the UK are worth reading if you are close to the eligibility boundary. You can also check your own figure with the NHS BMI calculator before any consultation.

If you are eligible, will Wegovy actually get you to 10 pounds lost, and what affects that?

For most people who meet the licensed criteria, a 10-pound loss is a realistic early outcome rather than a ceiling. Trial data suggest meaningful weight reduction starts in the first weeks and continues through the titration schedule. Individual responses vary: how quickly your appetite changes, how well you manage GI side effects in the early weeks, and how consistently you combine treatment with the recommended dietary and activity changes all affect the pace.

The dose schedule (starting low to let your system adjust, then stepped up by the prescriber over several months) means results at week 8 look different from results at week 40. People sometimes feel impatient around the month-two mark, which is often just before the bigger shifts come. It helps to know that ahead of time.

If you are weighing up Wegovy against other options, the eligibility and suitability overview covers who the medicine is and is not right for. For those curious whether a larger goal is realistic, losing 20 pounds on Wegovy walks through the evidence for bigger targets. Dosing frequency questions (such as whether the injection interval can be adjusted) are always a matter for your prescriber and the Patient Information Leaflet, not something to self-manage.

Side effects are worth knowing about before you start. The most common are gastrointestinal: nausea, loose stools, and sometimes constipation, particularly after starting or stepping up a dose. These are typically mild and settle within a week or two for most people. Serious side effects are rare but include acute pancreatitis; seek urgent help for severe, persistent stomach pain that reaches your back. You can report suspected side effects directly through the MHRA Yellow Card scheme.

On the cost side, Wegovy is not available on the NHS through most routes at present; private pricing varies by provider and dose. The cost and access page sets out what a legitimate private prescription typically involves. One transparent price that covers consultation, prescription, and delivery (no subscription, no auto-renewal) is what to look for from any regulated provider. If you are already using another weight loss medicine and wondering whether it can be combined with Wegovy, the guidance on taking orlistat alongside Wegovy is worth reading before raising it with your prescriber.